Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Tailor Made Compounding

tailormadecompounding.com ↗
Founded: 2013 HQ: Nicholasville, Kentucky Last reviewed: February 20, 2026
F
Overall Grade
Transparency 20/100
Testing 25/100
Pricing 50/100
Reputation 10/100
Compliance 5/100
Publishes COA No
Third-Party Testing No
FDA Warning Letters 1
Product Types injectable, compounded-prescriptions

Company Overview

Tailor Made Compounding (TMC) is a 503A compounding pharmacy based in Nicholasville, Kentucky, owned by Jeremy Delk. TMC has the most serious documented regulatory history of any vendor in our database, including a federal criminal conviction.

Regulatory History: The Record Speaks for Itself

Federal Criminal Conviction (October 2020)

TMC pleaded guilty to one felony count of distributing unapproved new drugs, including BPC-157, CJC-1295, Ipamorelin, LGD-4033, and others. The company agreed to forfeit $1,788,906.82 in proceeds. Owner Jeremy Delk received:

  • 3 years probation
  • 4 months home incarceration
  • $20,000 fine
  • Barred from prescription drug distribution

Obstruction of FDA Inspection (2018)

Prior to the criminal plea, Delk attempted to hide records from FDA inspectors during a 2018 inspection — conduct that contributed to the federal case.

Sterility Recall (2022)

TMC issued a sterility recall of compounded products in 2022, indicating ongoing quality control concerns even after the criminal conviction and sentencing.

Horse Racing Doping Connection

TMC has been connected to MediVet Equine and indicted individuals in a horse racing doping ring. The connection between compounding pharmacies producing unapproved peptides and their use in animal doping illustrates the breadth of the grey-market peptide ecosystem.

Current Status

Despite the federal criminal conviction, forfeiture of nearly $1.8 million, and the owner being barred from prescription drug distribution, the company continues to operate. This is perhaps the most remarkable fact in our assessment.

Scoring Rationale

Transparency: 20/100 — A company that attempted to hide records from FDA inspectors during an official inspection receives the lowest tier.

Testing: 25/100 — A sterility recall in 2022, two years after a criminal conviction for distributing unapproved drugs, indicates systemic quality failures.

Pricing: 50/100 — As a compounding pharmacy, pricing was within the normal range for compounded pharmaceuticals. This is the one area where TMC was not an outlier.

Reputation: 10/100 — A federal criminal conviction for distributing unapproved drugs, combined with obstruction of a federal inspection, represents a fundamental breach of consumer trust.

Compliance: 5/100 — A felony conviction and nearly $1.8 million in forfeiture is, by definition, a complete compliance failure.

Red Flags

  1. Federal criminal conviction for distributing unapproved drugs
  2. $1,788,906.82 forfeiture of criminal proceeds
  3. Owner attempted to hide records from FDA inspectors
  4. Sterility recall two years after conviction
  5. Connected to horse racing doping ring
  6. Owner barred from prescription drug distribution — yet company continues operating
  7. Continued operations despite the above

The Bottom Line

Tailor Made Compounding has a factual, documented regulatory history that includes a federal felony conviction, nearly $1.8 million in forfeited proceeds, obstruction of an FDA inspection, a sterility recall, and connections to animal doping. These are not allegations or concerns — they are adjudicated facts. We include this profile because TMC remains operational and consumers deserve access to this information when making purchasing decisions. The F grade reflects the documented record.